Get started
Keyword

elacestrant

Description: An oral estrogen receptor antagonist and degrader used to treat certain estrogen receptor-positive advanced breast cancers.
Wikidata ID: wiki/Q27278069
OpenAlex ID: keywords/elacestrant
Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial
2022 · Francois-Clement Bidard, Virginia G. Kaklamani, et al. · Journal of Clinical Oncology · 760
PDF
Elacestrant (RAD1901), a Selective Estrogen Receptor Degrader (SERD), Has Antitumor Activity in Multiple ER+ Breast Cancer Patient-derived Xenograft Models
2017 · Teeru Bihani, Hitisha K. Patel, et al. · Clinical Cancer Research · 162
Elacestrant in ER+, HER2− Metastatic Breast Cancer with ESR1 -Mutated Tumors: Subgroup Analyses from the Phase III EMERALD Trial by Prior Duration of Endocrine Therapy plus CDK4/6 Inhibitor and in Clinical Subgroups
2024 · Aditya Bardia, Javier Cortés, et al. · Clinical Cancer Research · 115
PDF
Next-generation selective estrogen receptor degraders and other novel endocrine therapies for management of metastatic hormone receptor-positive breast cancer: current and emerging role
2022 · Maxwell R. Lloyd, Seth A. Wander, et al. · Therapeutic Advances in Medical Oncology · 109
Phase I Study of Elacestrant (RAD1901), a Novel Selective Estrogen Receptor Degrader, in ER-Positive, HER2-Negative Advanced Breast Cancer
2021 · Aditya Bardia, Virginia Kaklamani, et al. · Journal of Clinical Oncology · 105
PDF
Latest generation estrogen receptor degraders for the treatment of hormone receptor-positive breast cancer
2021 · Ya-Chi Chen, Jiajie Yu, et al. · Expert Opinion on Investigational Drugs · 79
PDF
Elacestrant (RAD1901) exhibits anti-tumor activity in multiple ER+ breast cancer models resistant to CDK4/6 inhibitors
2019 · Hitisha K. Patel, Nianjun Tao, et al. · Breast Cancer Research · 75
PDF
The race to develop oral SERDs and other novel estrogen receptor inhibitors: recent clinical trial results and impact on treatment options
2022 · Yating Wang, Shou-Ching Tang · Cancer and Metastasis Reviews · 71
PDF
EMERALD: Phase III Trial of Elacestrant (RAD1901) vs Endocrine Therapy for Previously Treated ER+ Advanced Breast Cancer
2019 · Aditya Bardia, Philippe Aftimos, et al. · Future Oncology · 70
PDF
Elacestrant: First Approval
2023 · Sheridan M. Hoy · Drugs · 66
PDF
Novel endocrine therapies: What is next in estrogen receptor positive, HER2 negative breast cancer?
2023 · Chiara Corti, Carmine De Angelis, et al. · Cancer Treatment Reviews · 58
US Food and Drug Administration Approval Summary: Elacestrant for Estrogen Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative, ESR1 -Mutated Advanced or Metastatic Breast Cancer
2024 · Mirat Shah, Hima Lingam, et al. · Journal of Clinical Oncology · 51
PDF
A phase 1b study evaluating the effect of elacestrant treatment on estrogen receptor availability and estradiol binding to the estrogen receptor in metastatic breast cancer lesions using 18F-FES PET/CT imaging
2020 · Agnes Jager, Elisabeth G. E. de Vries, et al. · Breast Cancer Research · 49
PDF
Post-progression treatment options after CDK4/6 inhibitors in hormone receptor-positive, HER2-negative metastatic breast cancer
2025 · Taha Koray Sahin, Alessandro Rizzo, et al. · Cancer Treatment Reviews · 47
Current and emerging treatment approaches for hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer
2023 · Komal Jhaveri, Frederik Marmé · Cancer Treatment Reviews · 45
PDF
Abstract GS3-01: GS3-01 EMERALD phase 3 trial of elacestrant versus standard of care endocrine therapy in patients with ER+/HER2- metastatic breast cancer: Updated results by duration of prior CDK4/6i in metastatic setting
2023 · Aditya Bardia, Francois-Clement Bidard, et al. · Cancer Research · 43
Pharmacokinetic and Pharmacodynamic Studies of Elacestrant, A Novel Oral Selective Estrogen Receptor Degrader, in Healthy Post-Menopausal Women
2020 · Maureen G. Conlan, Erik F. J. de Vries, et al. · European Journal of Drug Metabolism and Pharmacokinetics · 43
PDF
Next-Generation Endocrine Therapies for Breast Cancer
2021 · Donald P. McDonnell, Suzanne E. Wardell, et al. · Journal of Clinical Oncology · 42
Palazestrant (OP-1250), A Complete Estrogen Receptor Antagonist, Inhibits Wild-type and Mutant ER-positive Breast Cancer Models as Monotherapy and in Combination
2023 · Alison D. Parisian, Susanna A. Barratt, et al. · Molecular Cancer Therapeutics · 41
PDF
Pharmacological insights on novel oral selective estrogen receptor degraders in breast cancer
2024 · Giorgio Guglielmi, Marzia Del Re, et al. · European Journal of Pharmacology · 40
Filling the Gap after CDK4/6 Inhibitors: Novel Endocrine and Biologic Treatment Options for Metastatic Hormone Receptor Positive Breast Cancer
2023 · Abhenil Mittal, Consolacion Molto Valiente, et al. · Cancers · 39
PDF
Oral SERDs changing the scenery in hormone receptor positive breast cancer, a comprehensive review
2024 · Mathilde Gheysen, Kevin Punie, et al. · Cancer Treatment Reviews · 30
The Diversity of Liquid Biopsies and Their Potential in Breast Cancer Management
2023 · Corinna Keup, Rainer Kimmig, et al. · Cancers · 25
PDF
Elacestrant: a new FDA-approved SERD for the treatment of breast cancer
2023 · Neha Bhatia, Suresh Thareja · Medical Oncology · 25
Elacestrant demonstrates strong anti-estrogenic activity in PDX models of estrogen-receptor positive endocrine-resistant and fulvestrant-resistant breast cancer
2022 · Sunil Pancholi, Nikiana Simigdala, et al. · npj Breast Cancer · 22
PDF
Works count: 371
Citation count: 2,908
Year
Topic
Type